Collegium Pharmaceutical Inc (COLL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $786.83M
Last updated: Nov 17, 2026 at 11:04 AM ET
Collegium Pharmaceutical Inc (COLL) Stock Forecast
Analysts expect Collegium Pharmaceutical (COLL) to earn $7.48 per share in the fiscal year ending Dec 31, 2026, on revenue of $831.97M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $7.16.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 5 | 62.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 4.3% and revenue estimates rise 1.9%.
- Fiscal year ending Dec 31, 2026
- $7.48
- EPS consensus, revenue $831.97M
- Fiscal year ending Dec 31, 2027
- $7.16
- EPS consensus, revenue $847.70M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.48 | $7.30 to $7.60 | 7 | $831.97M | $826.10M to $834.00M | 7 |
| Dec 31, 2027 | $7.16 | $5.06 to $8.16 | 7 | $847.70M | $748.50M to $888.10M | 7 |
Quarterly Estimates
The EPS consensus falls from $2.03 for the quarter ending Dec 31, 2026 to $1.62 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.03 | $1.86 to $2.15 | 10 | $226.07M | $212.07M to $235.52M | 9 |
| Mar 31, 2027 | $1.62 | $1.25 to $1.84 | 5 | $200.74M | $185.10M to $206.41M | 4 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.7% from $7.53.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $7.48 | $7.46 | $7.34 | $7.47 | $7.53 | -0.7% |
| Fiscal year ending Dec 31, 2027 | $7.16 | $7.26 | $6.65 | $6.77 | $6.97 | +2.6% |
| Quarter ending Mar 31, 2027 | $1.62 | $1.56 | $1.56 | $1.54 | $1.53 | +5.6% |
Frequently Asked Questions About COLL
What is the COLL stock forecast?
Consensus analyst estimates put Collegium Pharmaceutical's EPS at $7.48 for the fiscal year ending Dec 31, 2026, on revenue of $831.97M. The consensus rating from 8 analysts is Buy.
How do analysts rate COLL stock?
Of 8 analysts covering Collegium Pharmaceutical, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from COLL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $7.48, with estimates from $7.30 to $7.60 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.16, with estimates from $5.06 to $8.16 from 7 analysts.
What revenue do analysts expect from Collegium Pharmaceutical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $831.97M, with estimates from $826.10M to $834.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $847.70M, with estimates from $748.50M to $888.10M.
How many analysts cover COLL?
8 analysts rate Collegium Pharmaceutical stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
COLL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors